Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Clinical research specialists Accenture, Aptus, Boyds and KJC bring strong experience to CTDs orphan drug program
May 11, 2015
By: Tim Wright
Editor-in-Chief, Contract Pharma
Boyds has joined CTD Holdings’ International Clinical Program Team along with Aptus Clinical and KJC Statistics to develop orphan drug Trappsol Cyclo with Accenture. CTD Holdings, Inc. is a family of biotechnology companies that develop cyclodextrin-based treatments and other products. Trappsol Cyclo is used for the treatment of Niemann-Pick Type C, a rare and often fatal genetic disease that occurs primarily in young children. The company holds orphan designation for Trappsol Cyclo in Europe and is obtaining orphan drug designation in the U.S. It is currently being used as an investigational new drug on a compassionate use or named patient basis in Europe, Brazil and the U.S. Professor Alan Boyd, chief executive officer and founder of Boyds said, “Together our group has extensive experience in the development and commercialization of orphan drugs. We are delighted to bring this experience to CTD’s International Clinical Program for Trappsol Cyclo, which is being developed for a clear, unmet medical need.” President and chief executive officer of CTD Holdings, Dr. Jeffrey Tate, added, “We have assembled a powerful team for our International Clinical Program. The addition of Aptus, Boyds and KJC reflects our commitment to completing clinical trials quickly and making Trappsol Cyclo available to Niemann-Pick Type C patients around the world.” All parties have signed contracts and the project is now underway. Niemann-Pick Type C (NP-C) disease is a rare genetic disease where fatty molecules slowly build up in the body to levels that can eventually cause serious problems. NP-C affects infants, children and adults and affects about one in every 120,000 births worldwide.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !